scholarly article | Q13442814 |
P50 | author | Giovanni Palladini | Q37839091 |
Giampaolo Merlini | Q37839101 | ||
Laura Obici | Q56426698 | ||
Mario Nuvolone | Q56512662 | ||
Stefano Perlini | Q57005375 | ||
P2093 | author name string | Riccardo Albertini | |
Vittorio Perfetti | |||
Paola Russo | |||
Remigio Moratti | |||
Francesca Lavatelli | |||
Tiziana Bosoni | |||
P433 | issue | 4 | |
P921 | main subject | thalidomide | Q203174 |
dexamethasone | Q422252 | ||
AL amyloidosis | Q4652470 | ||
P304 | page(s) | 347-350 | |
P577 | publication date | 2008-09-09 | |
P1433 | published in | Annals of Hematology | Q15766509 |
P1476 | title | Treatment of patients with advanced cardiac AL amyloidosis with oral melphalan, dexamethasone, and thalidomide | |
P478 | volume | 88 |
Q36862339 | A phase II trial of cyclophosphamide, lenalidomide and dexamethasone in previously treated patients with AL amyloidosis. |
Q27023836 | Amyloid diseases of the heart: current and future therapies |
Q33867198 | Amyloidosis and POEMS syndrome |
Q35111771 | Amyloidosis: pathogenesis and new therapeutic options. |
Q42941866 | An unusual case of IgE-multiple myeloma presenting with systemic amyloidosis 2 years after cervical plasmacytoma resection |
Q58030146 | Bortezomib in a phase 1 trial for patients with relapsed AL amyloidosis: cardiac responses and overall effects |
Q42177959 | Cardioverter-defibrillator implantation in myeloma-associated cardiac amyloidosis |
Q46695052 | Clinical features and treatment outcome of primary systemic light-chain amyloidosis in Korea: results of multicenter analysis |
Q42662215 | Current treatment of AL amyloidosis |
Q38172998 | Future directions in the clinical management of amyloid light-chain amyloidosis |
Q46400142 | How to manage primary amyloidosis |
Q38970608 | Immunoglobulin Light Chain Systemic Amyloidosis |
Q37832199 | Immunoglobulin light chain amyloidosis: 2011 update on diagnosis, risk-stratification, and management |
Q26827340 | Immunoglobulin light chain amyloidosis: 2013 update on diagnosis, prognosis, and treatment |
Q34448455 | Immunoglobulin light chain amyloidosis: 2014 update on diagnosis, prognosis, and treatment |
Q38928383 | Immunoglobulin light chain amyloidosis: 2016 update on diagnosis, prognosis, and treatment |
Q37212712 | Lenalidomide, melphalan and dexamethasone in a population of patients with immunoglobulin light chain amyloidosis with high rates of advanced cardiac involvement |
Q38072108 | Light chain amyloidosis 2012: a new era. |
Q42958777 | Light chain amyloidosis: the heart of the problem |
Q41593651 | Long-term outcomes of primary systemic light chain (AL) amyloidosis in patients treated upfront with bortezomib or lenalidomide and the importance of risk adapted strategies |
Q39024208 | New and Evolving Concepts Regarding the Prognosis and Treatment of Cardiac Amyloidosis |
Q57904586 | Primary Systemic Amyloidosis (AL) |
Q37328204 | Treatment of hematologic neoplasms with new immunomodulatory drugs (IMiDs). |
Q37738576 | Treatment of immunoglobulin light chain amyloidosis |
Q82620976 | [Amyloidoses] |
Search more.